Reducing stroke disability is often achieved through endovascular clot removal in the acute phase, during the first 12 hours after a stroke. This regulatory approval marks the first therapy to show a reduction in global disability outside of that acute window. Further, the company is currently enrolling in the EMAGINE II pivotal study in the U.S. with the aim of achieving FDA clearance.

The BQ 2.0 system provides AI-powered, noninvasive, network-targeting electromagnetic precision therapy aimed at accelerating and enhancing the brain’s recovery from stroke. Delivered via a cloud-based platform, BRAIN.Q’s therapy is designed for seamless use by patients in both hospital and home settings.

“The past two decades have witnessed unprecedented advancements in our ability to efficiently train artificial intelligence learning systems. BRAIN.Q has harnessed these insights to design a precision therapy that helps the brain efficiently relearn and recover following a stroke. It’s a big step toward our vision of restoring brain health and dignity of life for stroke survivors,” said Yotam Drechsler, CEO and Co-founder of BRAIN.Q.